Verified July 2026 · Cited to primary sources
Selank: Evidence Grade C — Early / foreign human data only.
The honest verdict
Selank is not FDA-approved (it is approved in Russia) and there is no legal compounding route today — it was removed from 503A Category 2 but is not on the July 2026 PCAC docket. Human evidence is Grade C — several small Russian anxiety trials, including one where it matched a benzodiazepine, but no Western replication.
Selank at a glance
- Class
- Synthetic anxiolytic/nootropic heptapeptide (analog of the immunopeptide tuftsin)
- Mechanism
- A tuftsin analog that modulates GABA and serotonergic signaling and raises BDNF, and slows enkephalin degradation — an anxiolytic/nootropic peptide developed at the Russian Academy of Sciences.
- Also known as
- Thr-Lys-Pro-Arg-Pro-Gly-Pro, Tuftsin analog, N-acetyl Selank
- Research applications
- Generalized anxiety disorder and neurasthenia (Russian human trials)
- Cognition, focus and stress resilience (Russian clinical use; marketed as a nootropic)
- Forms
- intranasal spray/drops, subcutaneous injection
- Legal status
- Research-only
- WADA (anti-doping)
- Not explicitly prohibited (no growth-factor or hormone-secretagogue mechanism; note WADA's S0 catch-all can capture any non-approved substance)
- Evidence grade
- Grade CEarly / foreign human data only
How we grade evidence
Every grade is assigned by a fixed A–F rubric — human-trial strength, not hype or affiliate status. Last verified July 6, 2026.
What is Selank?
A Russian-developed anti-anxiety and nootropic peptide with real but non-Western human trials — in Russian studies it matched a benzodiazepine for anxiety without the sedation or dependence.
A tuftsin analog that modulates GABA and serotonergic signaling and raises BDNF, and slows enkephalin degradation — an anxiolytic/nootropic peptide developed at the Russian Academy of Sciences.
How strong is the evidence for Selank?
Grade C: approved as a drug in Russia and backed by several small Russian human anxiety trials — including one comparing Selank to the benzodiazepine medazepam in 62 patients with generalized anxiety disorder (decision-tree rule 4 fired — foreign approval with early/weak human RCTs). No FDA-recognized Western RCTs have replicated these results.
Primary sources (4)
- Zozulia et al., Zh Nevrol Psikhiatr Im S S Korsakova 2008 — Selank vs. medazepam in generalized anxiety disorder & neurasthenia (62 patients)
- Medvedev et al., Zh Nevrol Psikhiatr 2014 — anxiolytic effect and tolerability of Selank vs. phenazepam in anxiety disorders
- Medvedev et al., Zh Nevrol Psikhiatr 2015 — optimization of anxiety-disorder treatment with Selank
- FDA 503A bulks list (Selank removed from Category 2, awaiting PCAC review — not on the July 2026 docket)
Is Selank legal? (Status July 2026)
No legal supervised US route.
What is Selank used for?
Selank is marketed for the goals below. See how it ranks against other peptides in each — by evidence, not hype.
What does Selank cost — and how do you access it legally?
Typical cost
UNKNOWN
No verified US clinic price anchor; access is gray-market given the research-only status, so we don't quote or link a price.
No legal supervised access route right now.
Selank has no compliant US route today. Vials sold "for research use only" are a gray-market fig-leaf, not a legal loophole — we don't link them. If you pursue Selank, do it with a licensed clinician, and re-check its legal status first.
Is Selanksafe? Side effects & risks
Well tolerated in the Russian trials — no sedation, no withdrawal, and a benign side-effect profile were the headline findings versus the benzodiazepine comparators. The honest caveat: safety data comes almost entirely from Russian post-marketing use, the long-term Western profile is uncharacterized, and there is no legal supervised US route (Selank was removed from the 503A Category 2 list and is awaiting PCAC review, but is not on the July 2026 docket).
Medical disclaimer: This page is independent editorial information, not medical advice, and Best Peptide For That is not a medical provider. We do not provide dosing. Talk to a licensed clinician before starting, stopping, or changing any peptide or medication. Full medical disclaimer.
FAQ
Selank FAQ
Does Selank actually work for anxiety?
In Russian clinical trials, yes — one 62-patient study found Selank's anxiolytic effect comparable to the benzodiazepine medazepam, with added anti-fatigue effects and no sedation or dependence. But those are small Russian trials with no Western RCT replication, so on our scale Selank is Grade C — real early human data, not proven to FDA standards.
Is Selank FDA approved or legal?
Selank is not FDA-approved — it is an approved drug in Russia. In the US there is no legal supervised route: it was removed from the 503A Category 2 list but has not been scheduled at the July 2026 PCAC meeting, so it remains effectively research-only.
Is Selank the same as Semax?
No, but they're close cousins. Both are Russian-developed peptides with real but non-Western human data (both Grade C on our scale). Selank is the anti-anxiety/anti-stress peptide; Semax is the cognition/neuroprotection peptide. See our Semax page and our cognitive-peptides hub for the comparison.
Is Selank banned in sport?
Selank isn't explicitly named on the WADA Prohibited List and has no growth-factor or hormone-secretagogue mechanism. Tested athletes should still be cautious: WADA's S0 category is a catch-all for any substance with no regulatory approval for human therapeutic use.
Keep reading
Semax
A Russian-approved cognitive/neuroprotective peptide with real but non-Western clinical data.
Grade ATesamorelin
One of only two FDA-approved peptides in this space — proven to cut visceral fat, but approved for a narrow HIV indication.
Grade APT-141
One of only two FDA-approved peptides in this space — proven to raise sexual desire in premenopausal women, but the benefit is modest and the off-label hype outruns it.
The monthly peptide evidence brief.
What the research and the FDA actually say — one short email a month. Unsubscribe anytime.
No spam. We never sell your email. Editorial policy.